oa A new era in the management of diabetic kidney disease

References

1. World Health Organization . The top 10 causes of death; 2020 [Cited 2023 Dec 14]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.
   [Google Scholar]
2. Rai NK, Wang Z, Drawz PE, Connett J, Murphy DP. CKD Progression Risk and Subsequent Cause of Death: A Population-Based Cohort Study. Kidney Med. 2023 Jan 21; 5:(4):100604. doi: 10.1016/j.xkme.2023.100604.
   [Google Scholar]
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11; 329:(20):1456-62. doi: 10.1056/NEJM199311113292004.
   [Google Scholar]
4. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20; 345:(12):870-8. doi: 10.1056/NEJMoa011489.
   [Google Scholar]
5. Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco ALM, De Jong PE, et al. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for evaluating and managing chronic kidney disease. Kidney International Supplements. 2013; 3:(1):1-150. doi: 10.1038/kisup.2012.73.
   [Google Scholar]
6. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28; 375:(4):323-34. doi: 10.1056/NEJMoa1515920.
   [Google Scholar]
7. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24; 380:(4):347-357. doi: 10.1056/NEJMoa1812389.
   [Google Scholar]
8. Neal B, Perkovic V, Matthews DR. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Nov 23; 377:(21):2099. doi: 10.1056/NEJMc1712572.
   [Google Scholar]
9. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13; 380:(24):2295-2306. doi: 10.1056/NEJMoa1811744.
   [Google Scholar]
10. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8; 383:(15):1436-1446. doi: 10.1056/NEJMoa2024816.
    [Google Scholar]
11. The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12; 388:(2):117-127. doi: 10.1056/NEJMoa2204233.
    [Google Scholar]
12. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3; 383:(23):2219-2229. doi: 10.1056/NEJMoa2025845.
    [Google Scholar]
13. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov; 102:(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008.
    [Google Scholar]
14. American Diabetes Association. Standards of Care in Diabetes—2023 Abridged for Primary Care Providers. Clin Diabetes. 2023 Jan 2; 41:(1):4–31. doi: 10.2337/cd23-as01.
    [Google Scholar]